We are pleased to share this SuperCrowd Voices from the Community post with you. SuperCrowd Voices posts represent the views of our guest authors, not The Super Crowd, Inc., a public benefit corporation. Manage the volume of emails you receive from us by clicking here. Interested in sharing your voice? Click here.
Despite staggering investments in cancer treatments, most patients still face limited benefits—especially when diagnosed late. Jonathan Cohen, founder and CEO of 20/20 Biolabs, believes that the true key to saving lives lies not in better treatments, but in earlier detection.
“I saw massive funding of and spending by biotech companies in developing treatments, but very little going to companies focused on early disease detection and prevention, which can be far more impactful,” Cohen says. “Unlike with infectious disease, the effectiveness of treatments for cancer and most chronic diseases is quite limited. Even the latest approved cancer dru…




